Shervin Takyar, MD, PhD
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
I did my PhD in microbiology and molecular biology in The University of Queensland, Australia. During my PhD I worked and published on a variety of projects including developing a new lentiviral vector based on JDV (Jembrana Disease Virus), translational regulation in HCV by small RNA-binding molecules and the viral core protein, and RNA-protein interactions in positive strand RNA viruses. During this time I was also involved in cloning the Australian isolate of HCV with Dr Eric Gowans. My findings in these projects were published in a variety of journal including PNAS, Hepatology, and Journal of Molecular Biology.My next stop was a postdoctoral fellowship with Prof. Harry Noller at the RNA Center in UCSC where I delved deeper into the RNA world and studied the helicase activity of the ribosome during translation. Our work was well received and published in Cell.
I started my Internal Medicine residency at the State University of New York (SUNY) at Buffalo in 2003. During the last year of my residency I took part in a research project led by Dr Sands on the role of TIMP-1 in reactive airway disease. Our work was published in Clinical Immunology. I was then recruited to the Pulmonary Critical Care Fellowship at Yale in 2007, and worked with Dr J Elias to set up a platform for analyzing the role of microRNAs in the lung disease using the transgenic models that have been developed in his lab. I started this work on an inducible, lung-specific, VEGF transgenic model and within the first year of the project found a microRNA that was regulated by VEGF and mediated the effects of this cytokine in the lung. Based on these findings we filed a patent on the diagnostic and therapeutic use of miR-1 in lung disease. I received a K99/R00 award in the third year of my clinical fellowship for my work on this project. I was directly recruited as a tenure-track Assistant Professor in the Yale Pulmonary, Critical Care and Sleep Medicine Section at the end of my fellowship.
I started the R00 phase of my grant in 2014. I established my lab in the Pulmonary and Critical Care Section at Yale and was given a secondary appointment in the Department of Molecular Biophysics and Biochemistry. Focusing on the role of endothelial gene regulation in injury, I collaborated with Dr. P Lee a Yale to show that VEGF is a part of a TLR4-driven protective pathway in the lung endothelium. We showed the significance of this pathway in a variety of endothelial-specific models and published the results in FASEB journal in 2015.
In the next phase, we developed vector-based and transgenic models for endothelial-cell-specific miRNA expression and showed that miR-1 effects on inflammation and remodeling are due to its specific role in the lung endothelium. I started a collaboration with Yale Thoracic Interventional and Yale Thoracic Oncology programs on lung cancer and showed that miR-1 is a predictor of lung cancer survival and is regulated in tumor endothelial cells. As a part of this work we also set up several lung cancer models in the lab, including the KRAS mutant/P53 knockout mouse model I was awarded the American Lung Association Cancer Discovery Award in 2013, presented my findings at ATS in 2014, 2015, and 2016 and published a manuscript describing these results in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) in 2017.
I have followed my molecular studies on miR-1 in several directions. Our studies on the role of miR-1 in tumor endothelium has led to the identification of a novel non-templated addition (NTA) enzymatic pathway. We also found that PI3 kinase/Akt pathway controls miR-1 levels in the endothelium. We presented these findings at the Keystone symposium on “MicroRNAs and Noncoding RNAs,” at the “Lung Development, Injury and Repair” Gordon Research Conference in 2016, at the ATS in 2016, 2017, and 2018. We have continued our studies on the role of miR-1 in the tumor stroma and found that it is regulated in the cancerization field. The preliminary results from these studies were presented at ATS 2018 and 2019.
Following the specific role of miR-1 in the endothelium, we used our vascular specific miRNA expression models to probe the specific roles of endothelial miR-1 in airway inflammation. We also developed an Argonaute 2 cross-linking and immunoprecipitation (Ago-CLIP) method to identify novel miR-1 targets through miRISC analysis. Using these two methods we showed that isolated overexpression of miR-1 in the lung endothelium significantly decreases the severity of airway inflammation and mediates this mechanism through downregulation of eosinophil trafficking genes. Also, through our collaboration with Yale Center for Asthma and Airway Disease (YCAAD), and the Ear Nose Throat Department at Yale, we showed the significance of this miRNA-regulated gene network in human asthma and chronic rhinosinusitis. These findings were published in Journal of Allergy and Clinical Immunology (JACI) in 2020.
Since starting my tenure track position in 2010 I have been awarded the AAP (American Association of Physicians) Junior Investigator Award, ALA Lung Cancer Discovery Award, NIH/NIAID R56 award , ATS R to R award, and a DOD Lung Cancer Idea Development award. We have published our work on asthma and Th2 inflammation in Journal of Experimental Medicine, and Journal of Allergy and Clinical Immunology, our work on non-small cell lung caner tumor endothelium and cancer progression in the American journal of Respiratory and Critical Care Medicine, and our work on the role of endothelium in lung injury in FASEB journal. I have recruited and worked with five postdoctoral fellows, four Associate Research Scientists, and four students over the last seven years. My research currently focuses on the role of vascular non-coding RNAs in cancer, lung injury and airway inflammation.
Education & Training
- FellowYale University School of Medicine (2010)
- ResidentState University of New York - Buffalo (2006)
- FellowUniversity of California at San Cruz (2003)
- PhDUniversity of Queensland (2002)
- PG1University of Queensland (2001)
- MDIran University of Medical Sciences (1995)
Activities
- A. Korde, F. Ahangari, M. Haslip, G.L. Chupp, J. Pober, A. Gonzalez, J.L. Gomez, S. Takyar. Endothelial Thrombopoietin Receptor Regulates The Severity Of Type 2 Inflammation By Controlling PlateleteosinophilPhiladelphia, PA, United States 2020A. Korde, F. Ahangari, M. Haslip, G.L. Chupp, J. Pober, A. Gonzalez, J.L. Gomez, S. Takyar. Endothelial Thrombopoietin Receptor Regulates The Severity Of Type 2 Inflammation By Controlling Plateleteosinophil
- Gram Negative Infection Accelerates Lung Endothelial Cell Death Through Regulation of MicroRNA-1/Angiopoietin-2 PathwayDallas, TX, United States 2019A. Korde, S. Anderson, M. Haslip, S. Takyar. Gram Negative Infection Accelerates Lung Endothelial Cell Death Through Regulation of MicroRNA-1/Angiopoietin-2 Pathway
- Human Lung MicroRNA-1 Is Regulated by IL-13 and Correlates with Tissue Eosinophilia in Airway InflammationDallas, TX, United States 2019B. Hu, A. Korde, L.E. Cohn, J.-H. Chu, S. Takyar. Poster: Human Lung MicroRNA-1 Is Regulated by IL-13 and Correlates with Tissue Eosinophilia in Airway Inflammation
- Cigarette Smoke Activates PI3 Kinase Pathway and Downregulates MicroRNA-1 in Non-Small Cell Lung Cancer (NSCLC)Dallas, TX, United States 2019A. Korde, A. Ramaswami, M.S. Godfrey, S. Anderson, S. Takyar. Poster Discussion: Cigarette Smoke Activates PI3 Kinase Pathway and Downregulates MicroRNA-1 in Non-Small Cell Lung Cancer (NSCLC)
- Asthma is Associated with Benign Glandular Neoplasms in a Large-Scale Population-Based CohortSan Diego, CA, United States 2018Asthma is Associated with Benign Glandular Neoplasms in a Large-Scale Population-Based Cohort
- 3’-RNA Adenylation Enzymes Control Allergic Inflammation Through Regulation of MicroRNA DegradationSan Diego, CA, United States 20183’-RNA Adenylation Enzymes Control Allergic Inflammation Through Regulation of MicroRNA Degradation
- Eosinophil Binding and Activation is Regulated Through the Coordinated Expression of miR-1 Endothelial TargetsSan Diego, CA, United States 2018Eosinophil Binding and Activation is Regulated Through the Coordinated Expression of miR-1 Endothelial Targets
- A Herpesvirus Noncoding RNA Controls NSCLC Tumor Progression Through Selective Degradation of miR-27 in Immune CellsSan Diego, CA, United States 2018A Herpesvirus Noncoding RNA Controls NSCLC Tumor Progression Through Selective Degradation of miR-27 in Immune Cells
- RNA Modification Enzymes Control Non Small Cell Tumor Growth Through Regulation of the Angiogenic ResponseWashington, DC, United States 2017RNA Modification Enzymes Control Non Small Cell Tumor Growth Through Regulation of the Angiogenic Response
- RNA Modification Enzymes Control Non Small Cell Tumor Growth Through Regulation of the Angiogenic ResponseWashington, DC, United States 2017RNA Modification Enzymes Control Non Small Cell Tumor Growth Through Regulation of the Angiogenic Response
- Cell-specific MicroRNA-driven Pathway Controls the Recruitment of Eosinophils in Type 2 InflammationWashington, DC, United States 2017Cell-specific MicroRNA-driven Pathway Controls the Recruitment of Eosinophils in Type 2 Inflammation
- Cell-specific MicroRNA-driven Pathway Controls the Recruitment of Eosinophils in Type 2 InflammationWashington, DC, United States 2017Cell-specific MicroRNA-driven Pathway Controls the Recruitment of Eosinophils in Type 2 Inflammation
- MicroRNA-1 Levels Determine the Type of Inflammatory Remodeling in Chronic RhinosinusitisWashington, DC, United States 2017MicroRNA-1 Levels Determine the Type of Inflammatory Remodeling in Chronic Rhinosinusitis
- From inflammation to cancer: trials and tribulations of an endothelial microRNADenver, CO, United States 2016From inflammation to cancer: trials and tribulations of an endothelial microRNA
- Non-Small Cell Lung Cancer (NSCLC) Tumor Progression is Inhibited in an Inducible Vascular-Specific MicroRNA-1 (miR-1) Transgenic ModelSan Francisco, CA, United States 2016Non-Small Cell Lung Cancer (NSCLC) Tumor Progression is Inhibited in an Inducible Vascular-Specific MicroRNA-1 (miR-1) Transgenic Model
- VEGF Induces Lung Angiogenesis Through "Tailing and Trimming" of MicroRNAs and Production of 3'-Modified IsomiRsSan Francisco, CA, United States 2016VEGF Induces Lung Angiogenesis Through "Tailing and Trimming" of MicroRNAs and Production of 3'-Modified IsomiRs
- MiR-1 Expression in the Vicinity of Non-Small Cell Cancer Correlates with Patient SurvivalSan Francisco, CA, United States 2016MiR-1 Expression in the Vicinity of Non-Small Cell Cancer Correlates with Patient Survival
- Lung Endothelial miR-1 Recruits Angiopoietin-2 to RNA Induced Silencing Complex (RISC) and Protects Lungs against Oxidant Injury through an Angiocrine MechanismAndover, NH, United States 2015Lung Endothelial miR-1 Recruits Angiopoietin-2 to RNA Induced Silencing Complex (RISC) and Protects Lungs against Oxidant Injury through an Angiocrine Mechanism
- An Intrinsic Endothelial miR-1 Degradation Pathway Regulates Non-Small Cell Lung Cancer (NSCLC) Tumor Vascularity and ProgressionKeystone, CO, United States 2015An Intrinsic Endothelial miR-1 Degradation Pathway Regulates Non-Small Cell Lung Cancer (NSCLC) Tumor Vascularity and Progression
- Endothelial microRNA-1 Protects against Lung Hyperoxic Injury and Downregulates Ang2 ExpressionDenver, CO, United States 2015Endothelial microRNA-1 Protects against Lung Hyperoxic Injury and Downregulates Ang2 Expression
- An intrinsic endothelial miR-1 pathway controls vascular activation in asthma and lung cancerBethesda, MD, United States 2014An intrinsic endothelial miR-1 pathway controls vascular activation in asthma and lung cancer
- An Endothelial microRNA Circuit Controls Vascular Activation in Asthma and Lung CancerRahway, NJ, United States 2014An Endothelial microRNA Circuit Controls Vascular Activation in Asthma and Lung Cancer
- An Endothelial-specific VEGF Receptor 2-miR-1-Mpl Circuit Controls the Severity of Lung Th2 InflammationSan Diego, CA, United States 2014An Endothelial-specific VEGF Receptor 2-miR-1-Mpl Circuit Controls the Severity of Lung Th2 Inflammation
- Endothelial miR-1 is Downregulated in Lung Cancer Models and Controls the Progression of Lung Tumors through Inhibition of VEGF SignalingPhiladelphia, PA, United States 2013Endothelial miR-1 is Downregulated in Lung Cancer Models and Controls the Progression of Lung Tumors through Inhibition of VEGF Signaling
- TLR4 Protects the Lung Against Oxidant-induced Injury by Regulating the Endothelial Response to VEGFPhiladelphia, PA, United States 2013TLR4 Protects the Lung Against Oxidant-induced Injury by Regulating the Endothelial Response to VEGF
- MiR-1 Enters the RNA Induced Silencing Complex (RISC) in the Lung and Inhibits Th2 InflammationPhiladelphia, PA, United States 2013MiR-1 Enters the RNA Induced Silencing Complex (RISC) in the Lung and Inhibits Th2 Inflammation
- Mpl is Targeted by MiR-1 in the Lung Endothelial Cells and Regulates Th2 Inflammation by Controlling Adhesion Molecule ExpressionSan Francisco, CA, United States 2012Mpl is Targeted by MiR-1 in the Lung Endothelial Cells and Regulates Th2 Inflammation by Controlling Adhesion Molecule Expression
- MiR-1 Inhibits adaptive Th2 Inflammation in the Lung via a VEGF/Mpl AxisWaltham, MA, United States 2011MiR-1 Inhibits adaptive Th2 Inflammation in the Lung via a VEGF/Mpl Axis
- MicroRNA (miR)-1 Inhibits Adaptive Th2 Inflammation in the Lung via a VEGF/Myeloproliferative Leukemia Virus Oncogene (Mpl)-Dependent MechanismDenver, CO, United States 2011MicroRNA (miR)-1 Inhibits Adaptive Th2 Inflammation in the Lung via a VEGF/Myeloproliferative Leukemia Virus Oncogene (Mpl)-Dependent Mechanism
- Biology of Signaling in the Cardiovascular SystemBarnstable, MA, United States 2011Biology of Signaling in the Cardiovascular System
- MiR-1 inhibits Allergic Airway Inflammation by Targeting Mpl (Myeloproliferative Leukemia Virus Oncogene) in the Lung EndotheliumChicago, IL, United States 2011MiR-1 inhibits Allergic Airway Inflammation by Targeting Mpl (Myeloproliferative Leukemia Virus Oncogene) in the Lung Endothelium
- miR-1 Inhibits Adaptive Th2 Inflammation in the Lung via a VEGF/Myeloproliferative Leukemia Virus Oncogene (Mpl)-Dependent MechanismBanff, AB, Canada 2011miR-1 Inhibits Adaptive Th2 Inflammation in the Lung via a VEGF/Myeloproliferative Leukemia Virus Oncogene (Mpl)-Dependent Mechanism
- MiR-1 Regulates VEGF-induced Angiogenic Responses in the lung by Inhibiting the Myeloproliferative Leukemia Virus Oncogene (MPL)Seebruck, BY, Germany 2010MiR-1 Regulates VEGF-induced Angiogenic Responses in the lung by Inhibiting the Myeloproliferative Leukemia Virus Oncogene (MPL)
- MiR-1 Regulates VEGF-induced Angiogenic Responses in the lung by Inhibiting the Myeloproliferative Leukemia Virus Oncogene (MPL)New Orleans, LA, United States 2010MiR-1 Regulates VEGF-induced Angiogenic Responses in the lung by Inhibiting the Myeloproliferative Leukemia Virus Oncogene (MPL)
- MiR-1 is a Critical Regulator of VEGF-Induced AngiogenesisSan Diego, CA, United States 2009MiR-1 is a Critical Regulator of VEGF-Induced Angiogenesis
- Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Modulates Lung Hyperreactivity and Inflammation in a Murine Asthma ModelMiami, FL, United States 2006Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Modulates Lung Hyperreactivity and Inflammation in a Murine Asthma Model
- Mechanism and Control of Posttranscriptional Gene ExpressionNew York, NY, United States 2005Mechanism and Control of Posttranscriptional Gene Expression
- mRNA helicase activity of the ribosomeNew York, NY, United States 2005mRNA helicase activity of the ribosome
- A ribosomal helicase: unwinding mRNA during ribosomal translocationSan Francisco, CA, United States 2003A ribosomal helicase: unwinding mRNA during ribosomal translocation
- Cyanocobalamin-HCV IRES interaction: a molecular model for translational regulationStanford, CA, United States 2001Cyanocobalamin-HCV IRES interaction: a molecular model for translational regulation
- Cyanocobalamin can stall the ribosomal complexes on hepatitis C virus internal ribosomal entry site: a novel mechanism of translational controlSydney, NSW, Australia 2001Cyanocobalamin can stall the ribosomal complexes on hepatitis C virus internal ribosomal entry site: a novel mechanism of translational control
- Modulation of HCV IRES-dependent translation by HCV capsid proteinSydney, NSW, Australia 2001Modulation of HCV IRES-dependent translation by HCV capsid protein
- Exploring a natural role for cobalamins in hepatitis C virus replicationSydney, NSW, Australia 2001Exploring a natural role for cobalamins in hepatitis C virus replication
- Biochemical characterization of the cyanocobalamin-HCV IRES interaction: A novel mechanism of eukaryotic translational controlGold Coast, QLD, Australia 2000Biochemical characterization of the cyanocobalamin-HCV IRES interaction: A novel mechanism of eukaryotic translational control
- Probing the structure-function relationship in HCV internal ribosomal entry site using RNA pseudoknot binding moleculesGold Coast, QLD, Australia 2000Probing the structure-function relationship in HCV internal ribosomal entry site using RNA pseudoknot binding molecules
- Structure-function relationship in HCV internal ribosomal entry siteCairns, QLD, Australia 2000Structure-function relationship in HCV internal ribosomal entry site
- Specific detection of negative strand hepatitis C virus RNA by RT-PCR on poly A purified RNASydney, NSW, Australia 2000Specific detection of negative strand hepatitis C virus RNA by RT-PCR on poly A purified RNA
- Testing cobalamin-analogous compounds on HCV IRES-dependent translationSydney, NSW, Australia 2000Testing cobalamin-analogous compounds on HCV IRES-dependent translation
- Potential involvement of polypyrimidine tract binding protein in mediating interactions between the 5’UTR and 3’UTR of HCVSydney, NSW, Australia 2000Potential involvement of polypyrimidine tract binding protein in mediating interactions between the 5’UTR and 3’UTR of HCV
- RNA pseudoknot-binding molecules modulate HCV IRES-dependent translationSydney, NSW, Australia 2000RNA pseudoknot-binding molecules modulate HCV IRES-dependent translation
- Inhibition of Translation initiation in HCV: Implications for a novel antiviral drug designSydney, NSW, Australia 1999Inhibition of Translation initiation in HCV: Implications for a novel antiviral drug design
- The Role of 3’ U5 in a Novel Lentiviral Vector SystemMelbourne, VIC, Australia 1999The Role of 3’ U5 in a Novel Lentiviral Vector System
- Cytogenetic and epidemiologic study on 1100 trisomic 21 patientsShiraz, Fars Province, Iran 1998Cytogenetic and epidemiologic study on 1100 trisomic 21 patients
Honors & Recognition
Award | Awarding Organization | Date |
---|---|---|
Abstract Scholarship | American Thoracic Society, Respiratory Cell Molecular Biology Assembly | 2016 |
Abstract Scholarship | American Thoracic Society, Thoracic Oncology Assembly | 2015 |
Abstract Scholarship | American Thoracic Society, Allergy, Immunology and Inflammation Assembly | 2014 |
Junior Investigator Award | AAP/ASCI (American Association of Physicians/ American Society of Clinical investigators) | 2011 |
RNA Society Fellowship of BBSRC | Bitechnology and Biological Sciences Research Council | 2005 |
Graduate School Award | University of Queensland | 2000 |
Postgraduate Research Scholarship | University of Queensland | 1998 |
Professional Service
Organization | Role | Date |
---|---|---|
FASEB | Reviewer | 2017 - Present |
European Respiratory Journal | Reviewer | 2017 - Present |
American Thoracic Society International Conference, Poster Discussion Session: “MicroRNAs, RNAseq, LncRNA: Biology and Function" | Chair | 2016 |
American Journal of Physiology / Lung Cellular and Molecular Physiology | Reviewer | 2016 - Present |
American Journal of Respiratory and Critical Care Medicine | Reviewer | 2016 - Present |
Journal of Cell Biology | Reviewer | 2015 - Present |
Molecular Medicine | Reviewer | 2015 - Present |
Pulmonary Medicine and Respiratory Research | Editor | 2015 - Present |
Neuroscience Letters | Reviewer | 2014 |
Journal of Clinical Immunology | Reviewer | 2013 |
Departments & Organizations
- Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS)
- Center for RNA Science and Medicine
- Developmental Therapeutics
- Internal Medicine
- Pulmonary, Critical Care & Sleep Medicine
- Takyar Lab
- Winchester Center for Lung Disease
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Ventures